ClinicalTrials.gg
Active, not recruitingNCT06564194Updated Nov 5, 2026

A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

A Phase 1 interventional study of JCXH-108 and Placebo in Respiratory Syncytial Virus (RSV) and Infectious Disease, sponsored by Immorna Biotherapeutics, Inc.. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Immorna Biotherapeutics, Inc. · Phase 1, Interventional, and Prevention

How we know

Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 161 studies in Communicable Diseases with a site in United States — 29 open to participants now, 43 under way, none of them phase 3. Communicable Diseases · United States.

Enrollment
59th of 115
75 · median 78
Started
2024
with 7 others
Phase 1
20 of 161
1 open now
Primary completion
2024-12
later than 5 of 40 live
Registered
151st of 161
by date
Lead sponsor
4 of 161
Immorna Biotherapeutics, Inc.

Among the 161 studies in Communicable Diseases with a site in United States, this one is the 59th largest by enrollment of the 115 interventional ones that give a count, is one of 8 that started in 2024, is one of 20 in phase 1, reaches primary completion later than 5 of the 40 other live ones, and was the 151st registered.

Communicable Diseases

628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.

Browse Communicable Diseases studies →

Open to participants now

29 of the 161 studies in Communicable Diseases with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Communicable Diseases with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the safety, reactogenicity and immunogenicity of an mRNA-based vaccine, JCXH-108, the prevention of Respiratory Syncytial Virus (RSV) infection and diseases.

Participants will be randomized to receive either JCXH-108 or placebo.

Read the detailed description

This Phase 1 study plans to enroll a total of 75 participants.

Three cohorts with two different dose levels will be explored and each cohort will enroll 25 participants. Participants in each cohort will be randomized (4:1) to receive either JCXH-108 (n=20) or placebo (normal saline, n=5). A low dose of JCXH-108 will be explored vs placebo in the 18-45 years of age group first. A high dose will be explored vs placebo in the 18-45 years and ≥ 60 years of age groups once safety data is reviewed for the Sentinel subjects in the low dose cohort. The dose level of JCXH-108 will depend on the time the participant joins the study. Each participant will receive a single dose of JCXH-108 administered intramuscularly (IM) on day 1.

03

Conditions studied

  • Respiratory Syncytial Virus (RSV)
  • Infectious Disease

Browse trials for

Keywords

  • mRNA vaccine
  • RSV vaccination
  • Healthy subjects
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • Sex: Male or female; female subjects may be of or .
  • Age: 18-45 years of age or ≥ 60 years of age at screening
  • Status: Healthy subjects.
  • Subjects must agree to not be vaccinated with any RSV vaccine while participating in this study.
  • Subjects must agree to not be vaccinated with any RNA-based vaccines 30 days before D1 through 30 days after D1.

Main Exclusion Criteria:

  • Subjects with current diagnosis of RSV infection or diseases.
  • Previous vaccination against RSV.
  • Subjects with any respiratory illness deemed by the Investigator within the past month OR hospitalization >24 hours for any reason within the past month prior to Day 1.
  • Subjects with history of myocarditis or pericarditis, or with adverse events (AEs) after mRNA vaccination that are in nature and severity beyond the common expected AEs necessitating medical intervention.
  • Subjects who received any non- within 14 days prior to Day 1.
  • Subjects who received within 28 days prior to Day 1: (1) Any live vaccine, (2) Immunomodulators or immune-suppressive medication, (3) Granulocyte or granulocyte-macrophage colony-stimulating factor, and (4) Three or more consecutive days of systemic . Note: subjects on stable dose of steroid replacement (for chronic disease such as iatrogenic deficiency) of prednisone ≤10 mg/day or equivalent are allowed.
  • Subjects who currently receive other agents or devices.
  • Subjects with active or suspected , immunodeficiency, asplenia, recurrent severe infections or diseases. Certain immune-mediated conditions (e.g., Hashimoto thyroiditis) that are well controlled and stable are allowed.
  • Subjects receiving systemic antiviral therapy.
  • Subjects with a positive screening test for surface antigen (HBsAg), virus (HCV) antibodies, or anti-human -1 and 2 antibodies, syphilis.
  • Subjects with a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening or on Day 1 prior to vaccine administration (JCXH-108 or placebo).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Investigational product

    Subjects randomized to this arm will be given the investigational product (JCXH-108).

    Biological: JCXH-108

  • Placebo comparator
    Placebo

    Subjects randomized to this arm will be given a placebo.

    Other: Placebo

Interventions

  • BiologicalJCXH-108

    IM injection

  • OtherPlacebo

    IM injection

06

What researchers measure

Primary outcomes

  1. SAE Frequency

    Frequency of SAEs characterized by type, severity, duration, and relationship to the JCXH-108 recorded from Day 1 (D1) post-vaccine administration through follow-up completion.

    Time frame: Day 1 - Day 180 (6 Months)

  2. Injection site reaction

    Solicited local injection site reactions characterized by frequency, severity, and duration recorded within 30 days after administration after vaccine administration (JCXH-108 or Placebo)

    Time frame: Day 1 - Day 30

  3. Solicited systemic reaction frequency

    Solicited systemic adverse reactions characterized by frequency, severity, and duration recorded within 30 days after vaccine administration (JCXH-108 or Placebo)

    Time frame: Day 1 - Day 30

  4. AE frequency

    Adverse events (AEs) including unsolicited AEs characterized by type, severity, duration, and relationship to the vaccine (JCXH-108 or Placebo) recorded from Day 1 post-vaccine administration to within 30 days following vaccine administration

    Time frame: Day 1 -Day 30

  5. Medically attended AE frequency

    Medically attended AEs (MAAEs) characterized by frequency, severity, duration, and relationship to the vaccine (JCXH-108 or Placebo) recorded from Day 1 post-vaccine administration (JCXH-108 or Placebo) through follow-up completion

    Time frame: Day 1 - Day 180 (6 Months)

  6. Potential immune-mediated adverse events frequency

    Potential immune-mediated disease (pIMDs) characterized by frequency, severity, duration, and relationship to the vaccine (JCXH-108 or Placebo) recorded from Day 1 post-vaccine administration (JCXH-108 or Placebo) through follow-up completion

    Time frame: Day 1 - Day 180 (6 Months)

Secondary outcomes

  1. RSV-A and RSV-B antibody levels

    Levels of serum neutralizing antibodies against RSV-A and RSV-B as compared to Day 1 pre-dose (baseline) at Day 29, Month 3 and Month 6 after the vaccine administration

    Time frame: Day 1 - Day 180 (6 Months)

  2. IgG antibody levels

    Levels of serum RSV pre-F antibodies of IgG1, IgG2, IgG3, and IgG4 as compared to Day 1 pre-dose (baseline) at Day 29, after the vaccine administration. Measured in women of childbearing potential only.

    Time frame: Day 1 - Day 30

Other outcomes

  1. T-cell responses

    T-cell responses to vaccine-encoded antigen in peripheral blood mononuclear cells (PBMCs) determined by enzyme-linked immunosorbent spot (ELISpot) and Intracellular Cytokine Staining (ICS) assays, as compared to baseline (Day 1 pre-dose) at 29 days and 6 months after the vaccine administration (Day 30 and Month 6).

    Time frame: Day 1 -Day 180 (6 Months)

07

Study locations

3 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Dec 2024, 2 months.

Of 25 phase 1 interventional studies under Communicable Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 2 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jun 2026 → Dec 2024 and completion Jun 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 21, 2024
StartActual
Sep 25, 2024
Primary completionActual
Dec 12, 2024was Jun 2026
CompletionEst.
Dec 30, 2026was Jun 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Dec 12, 2024 (actual)
Nov 5, 2026
Study completion
Jun 2026→Dec 30, 2026
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Jun 2026→Dec 12, 2024 (now actual)
    Study completion Jun 2026→Dec 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06564194
Lead sponsor
Immorna Biotherapeutics, Inc.
Collaborators
Tigermed Consulting Co., Ltd
Responsible party
Sponsor
First posted
Aug 21, 2024
Start date
Sep 25, 2024
Primary completion
Dec 12, 2024
Completion
Dec 30, 2026 (estimated)
Last update
Nov 5, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion